GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of ADXS
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Advaxis stock price up 0.351% on Friday
(Updated on Apr 19, 2024)

Sell candidate since Apr 03, 2024 Loss -8.77% PDF

The Advaxis stock price gained 0.351% on the last trading day (Friday, 19th Apr 2024), rising from $0.570 to $0.572. During the last trading day the stock fluctuated 4.90% from a day low at $0.572 to a day high of $0.600. The price has risen in 5 of the last 10 days but is still down by -5.77% for this period. Volume fell on the last day by -7 thousand shares and in total, 2 thousand shares were bought and sold for approximately $1.41 thousand. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -10.43% during the next 3 months and, with a 90% probability hold a price between $0.351 and $1.07 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

ADXS Signals & Forecast

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Advaxis stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.621 and $0.666. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, February 06, 2024, and so far it has fallen -56.34%. Further fall is indicated until a new bottom pivot has been found. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may not be. The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Advaxis stock

Advaxis finds support from accumulated volume at $0.570 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day, but be aware of low or falling volume as this increases the risk. During the last day, the stock moved $0.0280 between high and low, or 4.90%. For the last week the stock has had daily average volatility of 9.31%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (ADXS) For The Upcoming Trading Day Of Monday 22nd

For the upcoming trading day on Monday, 22nd we expect Advaxis to open at $0.581, and during the day (based on 14 day Average True Range), to move between $0.501 and $0.643, which gives a possible trading interval of +/-$0.0708 (+/-12.37%) up or down from last closing price. If Advaxis takes out the full calculated possible swing range there will be an estimated 24.74% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $0.570 (0.35%) than the resistance at $0.600 (4.90%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Advaxis stock A Buy?

Advaxis holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -6.034 Strong Sell Candidate Unchanged

Predicted Opening Price for Advaxis of Monday, April 22, 2024

Fair opening price April 22, 2024 Current price
$0.581 ( 1.63%) $0.572

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ADXS

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 0.609 6.53 %
R2 0.599 4.66 %
R1 0.592 3.50 %
Current price: 0.572
Support S1 0.571 -0.238 %
S2 0.564 -1.39 %
S3 0.553 -3.26 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0.700 22.38 %
R2 0.670 17.13 %
R1 0.600 4.90 %
Current price 0.572
Support S1 0.570 -0.350%
S2 0.549 -3.94%
S3 0.520 -9.09%

FAQ

What is the symbol for Advaxis Stock and on which exchange is it traded?
The symbol for Advaxis is ADXS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Advaxis Stock?
Advaxis holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Advaxis Stock?
Advaxis Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Advaxis Stock.

What's the current price of Advaxis Stock?
As of the end of day on the 2024-04-19, the price of an Advaxis (ADXS) share was $0.572.

What is the 52-week high and low for Advaxis Stock?
The 52-week high for Advaxis Stock is $1.95 and the 52-week low is $0.500.

What is the market capitalization of Advaxis Stock?
As of the 2024-04-19, the market capitalization of Advaxis is 27.52M.

When is the next earnings date for Advaxis?
The upcoming earnings date for Advaxis is Aug 08, 2024.
Click to get the best stock tips daily for free!

About Advaxis

Advaxis Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for... ADXS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT